These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

758 related articles for article (PubMed ID: 12756192)

  • 1. Eplerenone: cardiovascular protection.
    Brown NJ
    Circulation; 2003 May; 107(19):2512-8. PubMed ID: 12756192
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pleiotropic actions of aldosterone and the effects of eplerenone, a selective mineralocorticoid receptor antagonist.
    Takeda Y
    Hypertens Res; 2004 Nov; 27(11):781-9. PubMed ID: 15824460
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Eplerenone: a selective aldosterone receptor antagonist for hypertension and heart failure.
    Moore TD; Nawarskas JJ; Anderson JR
    Heart Dis; 2003; 5(5):354-63. PubMed ID: 14503934
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Eplerenone for the treatment of cardiovascular disorders.
    Watanabe M; Krum H
    Expert Rev Cardiovasc Ther; 2012 Jul; 10(7):831-8. PubMed ID: 22908915
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Review article: eplerenone: an underused medication?
    Abuannadi M; O'Keefe JH
    J Cardiovasc Pharmacol Ther; 2010 Dec; 15(4):318-25. PubMed ID: 20876342
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The role of aldosterone receptor blockade in the management of cardiovascular disease.
    Liew D; Krum H
    Curr Opin Investig Drugs; 2002 Oct; 3(10):1468-73. PubMed ID: 12431020
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Eplerenone--a novel selective aldosterone blocker.
    Zillich AJ; Carter BL
    Ann Pharmacother; 2002 Oct; 36(10):1567-76. PubMed ID: 12243608
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recent studies with eplerenone, a novel selective aldosterone receptor antagonist.
    McMahon EG
    Curr Opin Pharmacol; 2001 Apr; 1(2):190-6. PubMed ID: 11714095
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Symptoms and the distress they cause: comparison of an aldosterone antagonist and a calcium channel blocking agent in patients with systolic hypertension.
    Hollenberg NK; Williams GH; Anderson R; Akhras KS; Bittman RM; Krause SL
    Arch Intern Med; 2003 Jul; 163(13):1543-8. PubMed ID: 12860576
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Eplerenone. Pharmacia.
    Liew D; Martin J; Krum H
    Curr Opin Investig Drugs; 2003 Mar; 4(3):316-22. PubMed ID: 12744223
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Eplerenone: a selective aldosterone receptor antagonist (SARA).
    Delyani JA; Rocha R; Cook CS; Tobert DS; Levin S; Roniker B; Workman DL; Sing YL; Whelihan B
    Cardiovasc Drug Rev; 2001; 19(3):185-200. PubMed ID: 11607037
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of the aldosterone-blocking agent eplerenone in hypertension and heart failure.
    George J; Struthers AD
    Expert Opin Pharmacother; 2007 Dec; 8(17):3053-9. PubMed ID: 18001264
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Eplerenone: selective aldosterone antagonism in management of cardiovascular and renal disease.
    Brennan BJ; Martin NE
    J Am Pharm Assoc (2003); 2004; 44(5):604-10; quiz 610-1. PubMed ID: 15496047
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Eplerenone, a new selective aldosterone blocker.
    McMahon EG
    Curr Pharm Des; 2003; 9(13):1065-75. PubMed ID: 12678858
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Eplerenone: a selective aldosterone receptor antagonist for patients with heart failure.
    Barnes BJ; Howard PA
    Ann Pharmacother; 2005 Jan; 39(1):68-76. PubMed ID: 15590870
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mineralocorticoid receptor antagonists.
    Parthasarathy HK; MacDonald TM
    Curr Hypertens Rep; 2007 Mar; 9(1):45-52. PubMed ID: 17362671
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular mechanisms of mineralocorticoid receptor antagonism by eplerenone.
    Hu X; Li S; McMahon EG; Lala DS; Rudolph AE
    Mini Rev Med Chem; 2005 Aug; 5(8):709-18. PubMed ID: 16101407
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evolving role of aldosterone blockers alone and in combination with angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers in hypertension management: a review of mechanistic and clinical data.
    Black HR
    Am Heart J; 2004 Apr; 147(4):564-72. PubMed ID: 15077068
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Pharmacological sheet: eplerenone (Inspra), orally].
    J Pharm Belg; 2011 Sep; (3):93-4. PubMed ID: 21995102
    [No Abstract]   [Full Text] [Related]  

  • 20. Aldosterone antagonists in heart failure.
    Guglin M; Kristof-Kuteyeva O; Novotorova I; Pratap P
    J Cardiovasc Pharmacol Ther; 2011 Jun; 16(2):150-9. PubMed ID: 21160084
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 38.